Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Roxadustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 known ✓ | Q9GZT9 | 9/20 | 1.00 |
| ▸ | EGLN2 known ✓ | Q96KS0 | 1/20 | 0.80 |
| ▸ | THRA | P10827 | 13/20 | 1.00 |
| ▸ | THRB | P10828 | 13/20 | 1.00 |
| ▸ | BBOX1 | O75936 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
| ▸ | KDM8 | Q8N371 | 1/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roxadustat SCHEMBL29892426 | 1.00 | THRA (1.00) | THRATHRBEGLN1BBOX1SLC6A2 | |
| Roxadustat SCHEMBL29350689 | 1.00 | THRA (1.00) | THRATHRBEGLN1BBOX1SLC6A2 | |
| Roxadustat SCHEMBL15421135 | 0.99 | THRA (0.98) | THRATHRBEGLN1BBOX1SLC6A2 | |
| Roxadustat SCHEMBL15421137 | 0.99 | THRA (0.98) | THRATHRBEGLN1BBOX1SLC6A2 | |
| Roxadustat SCHEMBL15421357 | 0.99 | THRA (0.98) | THRATHRBEGLN1BBOX1SLC6A2 | |
| Roxadustat SCHEMBL15421446 | 0.99 | THRA (0.98) | THRATHRBEGLN1BBOX1SLC6A2 | |
| Roxadustat SCHEMBL15421351 | 0.99 | THRA (0.98) | THRATHRBEGLN1BBOX1SLC6A2 | |
| Roxadustat SCHEMBL15421447 | 0.99 | THRA (0.98) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL522741 | 0.96 | EGLN1 (1.00) | THRATHRBEGLN1BBOX1SLC6A2 | |
| Roxadustat SCHEMBL15549628 | 0.95 | THRA (0.90) | THRATHRBEGLN1BBOX1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 543 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357628-B2 | Prevention and treatment of organ fibrosis | CORNELL UNIVERSITY (US) | 2025-07-15 | — | — | US | claimed |
| CN-115703729-A | Process for producing glycine derivative | 四川科伦药物研究院有限公司 | 2023-02-17 | — | — | CN | claimed |
| CN-109956901-B | Preparation method of isoquinolone compound | 南京正大天晴制药有限公司 | 2022-09-06 | — | — | CN | claimed |
| EP-4029854-A1 | CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR | Fibrogen, Inc. (US) | 2022-07-20 | — | — | EP | claimed |
| US-20220054474-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | FIBROGEN, INC. | 2022-02-24 | — | — | US | claimed |
| EP-3470397-B1 | CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR | FIBROGEN INC (US) | 2021-12-29 | — | — | EP | claimed |
| WO-2021073623-A1 | METHOD FOR PREPARING ISOQUINOLINONE COMPOUNDS | 上海迪赛诺化学制药有限公司 | 2021-04-22 | — | — | WO | claimed |
| CN-108017583-B | Preparation method of kebomei | 徐州万邦金桥制药有限公司 | 2021-04-06 | — | — | CN | claimed |
| US-20200397777-A1 | PREVENTION AND TREATMENT OF ORGAN FIBROSIS | CORNELL UNIVERSITY | 2020-12-24 | — | — | US | claimed |
| CN-108434139-B | Application of hypoxia-inducible factor prolyl hydroxylase activity inhibitor in preparation of medicine for preventing and treating acute kidney injury | 南京市儿童医院 | 2020-10-16 | — | — | CN | claimed |
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | claimed |
| US-7323475-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2008-01-29 | — | — | US | claimed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | claimed |
| US-20060276477-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2006-12-07 | — | — | US | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | EGLN1 863/4885EGLN2 370/4885THRA 3799/4885 |
| US-12357628-B2 | Prevention and treatment of organ fibrosis | MMP1, P4HA1, SERPINH1 | EGLN1 1390/4885EGLN2 278/4885THRA 4453/4885 |
| US-20060276477-A1 | Treatment method for anemia | THPO, EPOR, MPL | EGLN1 85/4885EGLN2 8/4885THRA 247/4885 |
| US-20200397777-A1 | PREVENTION AND TREATMENT OF ORGAN FIBROSIS | MMP1, P4HA1, SERPINH1 | EGLN1 1390/4885EGLN2 278/4885THRA 4453/4885 |
| US-20220054474-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885EGLN2 3/4885THRA 1963/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | EGLN1 16/4885EGLN2 4/4885THRA 1089/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | EGLN1 12/4885EGLN2 5/4885THRA 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.